Mayne Pharma Management Changes
Filed with ASX · · 3 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call23 February 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces a planned leadership transition. On 20 February 2026 (US time) Mr Shawn Patrick O’Brien stepped down as Chief Executive Officer and Managing Director, and Mr Aaron Gray, currently Mayne Pharma’s Chief Financial Officer, was appointed Chief Executive Officer. Mr O’Brien joined
Mayne Pharma Group Ltd. on 6ix
In the deck
Earlier from Mayne Pharma
- MYX to claim against Cosette, Avista & Mr David Burgstahler
- 2025 AGM presentation and business update
- Market Update
- Termination of Proposed Acquisition of Mayne Pharma
- Mayne Pharma terminates Scheme Implementation Deed
Later from Mayne Pharma
- Half Yearly Report and Accounts
- 2026 Half Year Media Release
- 2026 Half Year Investor Presentation
- S&P DJI Announces March 2026 Quarterly Rebalance
- Mayne Pharma reports unaudited 3Q FY26 results
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma